Presentation is loading. Please wait.

Presentation is loading. Please wait.

Modernising community pharmacy in Scotland- how do we know what the stakeholders want? Christine Bond Department of General Practice and Primary Care and.

Similar presentations


Presentation on theme: "Modernising community pharmacy in Scotland- how do we know what the stakeholders want? Christine Bond Department of General Practice and Primary Care and."— Presentation transcript:

1 Modernising community pharmacy in Scotland- how do we know what the stakeholders want? Christine Bond Department of General Practice and Primary Care and NHS Grampian

2 Acknowledgements Research colleagues –Terry Porteous, Mandy Ryan, Tony Scott, Michela Tinelli –Phil Hannaford, Sally Wyke Funders –Chief Scientist Office, MRC/ESRC, NHS R and D

3 Traditional NHS contracts

4 Traditional contracts Dispensing of prescriptions –volume driven payment Displaying leaflets Providing opportunistic advice on dispensed medicines –professional fee Locally negotiated services –eg drug misusers, nursing homes, compliance needs assessment, smoking cessation Recognition of other private health care roles –Sales of OTC medicines

5 New UK community pharmacy contracts (Smoking, Health and Social Care (Scotland) Act 2005) Scotland (from July 2006) –Four core services provided by all pharmacies Minor Ailments (MAS) Public Health (PHS) Chronic Medicines Service (CMS) Acute Medicines Service (AMS) –Pharmaceutical Care Services Plan –Locally negotiated services based on national specifications –Performers List –Supplementary (and Independent) prescribing –OTC sales function still not NHS

6 New contracts

7 Drivers for change Research data Policy, culture/society change Practice norms

8 Drivers for change Research data Policy, culture/society change Practice norms GP workload Convenienc e Skills mix Drug budgets Expectations Relationships

9 Drivers for change Research data Policy, cu lture/society change Practice norms GP workload Convenienc e Skills mix Drug budgets Expectations Relationships DCE

10 New responsibilities for pharmacy NHS role in self care and provision of advice and supply of medicines –Community pharmacy led treatment of minor illness Chronic medicines review and supply –Medication review –Repeat dispensing –Prescribing pharmacists What do pharmacists think? What do patients think? DCEs could have informed both of these

11 Will stakeholders accept new policies? Patients DCEs have been used to assess –What patients value in repeat dispensing Bond, C.M., Matheson C., Jones, J., Williams, S. Repeat prescribing study: an evaluation of the role of community pharmacists in controlling and monitoring repeat prescribing, following protocols agreed with the general practitioner.Report to the Grampian Health Board February 1997 –Acceptability of prescribing pharmacist Tinelli M., Ryan M., Bond C.,Patient preferences for increasing the role of the pharmacist in the management of drug therapy IJPP 2004 12 (R93) –Pharmacist role in medication review Tinelli M., Ryan M., Bond C., Economic evaluation advancement in pharmacy: discrete choice experiments IJPP 2007 15 A12 –The publics preferences in self care Porteous, T., Ryan, M., Bond, C., Hannaford, P. Preferences for self-care or consulting a health professional in minor illness; a discrete choice experiment BJGP 2006 911-17

12 Will stakeholders accept new policies? Pharmacists –Pharmacists preferences for contractual changes Scott. A, Bond, C.M., Inch. J, Grant. A, Preferences of Community Pharmacists for Extended Roles in Primary Care – A Survey and Discrete Choice Experiment. Pharmacoeconomics 2007;25 (9) 983-792 –Pharmacists preferences for different attributes of an electronic data interchange system Ubach, C., Bate, A.,Ryan, M., Porteous, T., Bond, C., Robertson, R. Using discrete choice experiments to evaluate alternative electronic prescribing systems.. Int.J.Pharm. Pract 2002; 10:191-200 –Pharmacists decision making in OTC advice Roins S, Benrimoj SI, Carroll PR et al Pharmacistsrecommendation of the active ingredient(s) of non-prescription analgesics for a simple tension and migraine headache JSAP 1998; 15:262-274

13 Terry Porteous, Christine Bond, Phil Hannaford, Mandy Ryan, Sally Wyke Managing minor illness Factors influencing the choice between self-care and health professional advice: a discrete choice experiment.

14 Study design Qualitative interviews Aim - To describe what factors influence patients when deciding how to manage minor ailments associated with analgesic use Discrete choice experiment Aim - To describe what trade-offs people make when deciding how to manage minor ailments associated with analgesic use

15 Qualitative interviews 24 interviews across Scotland asking about: recent experience and management of symptoms associated with analgesic use. reasons for practising self-care and/or consulting health professionals opinions on self-care and use of analgesics

16 Influencing factors Reasons for practising self- care Faster treatment/easier access Use of complementary treatments Avoidance of unwanted treatments Feelings of control/independence Previous experience of same symptoms Advice from friends, relatives or media Perception that condition is self- inflicted Belief that GP will be of limited help Does not want to waste Drs time Reasons for not practising self-care Having to pay for treatments yourself No advice from Dr/pharmacist Chance of missing important condition Chance of drug interactions Chance of making things worse Belief that nothing can help or stoicism Lack of knowledge Belief that only medical help will work

17 The attributes The influencing factors Type of management (self-care, GP, pharmacy, practice nurse, complementary, NHS24, do nothing) Time to treatment (the time you have to wait for an appointment, travel time and time taken to get any treatment) (0,1,5 hours, 1,2,5 days) Cost (travel costs and the cost of any treatment e.g. any consultation fee, over-the-counter medicines, complementary remedies etc.)(£2, £5, £7, £15)

18 The scenario Please imagine this situation: You have a headache and a fever, your bones are aching and your nose feels slightly blocked up. You are still able to do all the things you usually do but are more tired than usual. The symptoms started to appear four days ago, and were slightly worse when you woke up this morning.

19 A sample question Option 1Option 2 Type of management Self-careGP Availability1 hour2 days Cost £2£7 (Tick ONE box only) Option 1 Option 2 Do nothing Example Which option would you choose?

20 DCE analysis and results DCE administered during November 2005 Response rate of 57% (326/573) Analysed using multinomial logistic regression Regression coefficients used to estimate - utility (preferences or satisfaction) - willingness-to-pay

21 Overall preferences For the symptoms presented: Respondents had a general preference for doing something (rather than do nothing) Relative preferences for type of management: Self-care Community pharmacy GP consultation Practice nurse NHS24 Complementary Decreasing preference

22 Conditional logit regression analysis

23 Respondents valued self-care at £22.62 i.e they were prepared to pay up to £22.62 to treat these symptoms by self-care but beyond this price, they would rather do nothing. Willingness to pay

24 They valued other treatment options less highly e.g. they would pay £17.01 LESS than this to treat symptoms using the NHS24 option

25 Willingness to pay They were prepared to pay £3.69 to reduce the wait to treat symptoms by 1 day

26 Moving from one service to another Service 1Service 2 Type of management Telephone advice from NHS24 Ask for advice in a pharmacy Wait before treating symptoms 5 hours1 day

27 Moving from one service to another Service 1Service 2 Type of management Telephone advice from NHS24 β = -1.48 Ask for advice in a pharmacy β = -0.304 Wait before treating symptoms 5 hours β = 5/24*-0.321 1 day β = -0.321 Utility of a service = Constant (1.968) +β (service) Moving from NHS24 to pharmacy management gives an increase in utility ie β (NHS24) – β (pharmacy) = -1.48 – (-0.304) = -1.176

28 Moving from one service to another Service 1Service 2 Type of management Telephone advice from NHS24 Ask for advice in a pharmacy Wait before treating symptoms 5 hours β = 5/24*-0.321 1 day β = -0.321 Utility of a service = Constant (1.968) +β (service) Moving from a wait of 5 hours to 1 day gives a decrease in utility ie β (5 hours) – β (1 day) = -0.067 – (-0.321) = 0.254

29 Moving from one service to another Service 1Service 2 Type of management Telephone advice from NHS24 Ask for advice in a pharmacy Wait before treating symptoms 5 hours1 day Overall difference in utility is positive and we can quantify it by WTP U (service 1) – U (service 2) / β (cost) = 0.421-1.343/-0.087 = £10.60 Rather than get telephone advice from NHS24 with a 5 hour wait, a respondent would be willing to pay an extra £10.60 to get advice from a pharmacy with a wait of 1 day

30 Conclusions Self-care was the preferred way of dealing with these symptoms It was highly valued by respondents Community pharmacy was the preferred source of professional advice DCE allowed quantification of preferences and expressed them by WTP

31 Assessing what patients liked about pharmacist led medicine management Tinelli M, Ryan M, Bond C

32 Aim: to evaluate the introduction of the Medicines Management Service by community pharmacists for patients with CHD Randomised Controlled Trial Setting: Nine Health Authorities in England, 50 Community pharmacies, 39 General Practices Primary subjects: Patients with CHD Intervention: Community Pharmacy face-to-face patient review to include medication and lifestyle advice Control: Usual care The Community Pharmacy Medicines Management Project* The Community Pharmacy medicines Management Project Evaluation team (C. Bond Principal Investigator) The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Family Practice 2007; 24(2):189-200

33 Primary outcome measures: appropriate treatment (derived from the NSF), health status (EQ5D and SF36) Secondary outcome measures: satisfaction, experiences and attitudes of patients and health care professionals Time period: All measures were assessed at baseline and 12 months Results: no changes in clinical or QALY outcomes; patients satisfaction higher in the intervention group To use a DCE to –Explain the increased satisfaction –Inform a CBA for the community pharmacy-led medicines management service The Community Pharmacy Medicines Management Project The Community Pharmacy Medicines Management Project

34 Identification of attributes from replies to patient survey DCE survey questionnaires sent to all patients participating to the trial 2 years after study start (879 intervention; 470 control) DCE compared three options: –a novel community pharmacist and general practitioner review of medicines (CPGP) –a GP only medicines review (GP) –the current scenario WTP in moving from the current situation to CPGP or GP were estimated Groups compared: –intervention all vs control (TAU) (ITTA) –intervention still receiving the Medman service vs control (TAU) (PPA) A priori assumed people who had experienced the service more likely to value it Use of DCE

35 Attributes Advice –None, only on medicines, only on health/lifestyle, both Time (travelling to and in the pharmacy) –10,20,30,40 min Privacy (in the pharmacy) Satisfactory replies to questions –Yes, No Chance of receiving most appropriate treatment –Very poor, poor, good, very good How much you pay ( medicine + advice+ review+ travel) –£0, £10, £20, £30

36 Example of DCE choice Medicines review by GP and Pharmacist Medicines review by GP only Current situation ADVICEOn medicine & health/lifestyle No PRIVATE DISCUSSION YesNo SATISFACTORY REPLIES YesNo CHANCE OF APPROPRIATE TREATMENT Very good TIME (Travelling to + waiting in the pharmacy) 10 minutes HOW MUCH YOU HAVE TO PAY (Consultation + medicines + travelling) £ 10 WHICH SERVICE WOULD YOU CHOOSE? (Tick one box only)

37 Results Response rates: Intervention (73%) and Control (67%) 44% of intervention still receiving the service, 52% stopped, 4% never The preferred option for all groups was the current option Controls: –Chance of receiving the best medicine and cost were most important –If moving from the current service would choose the GP only option

38 Intervention groups Intervention all –Advice on medicines, satisfactory replies as well as chance of receiving the best medicine and cost were most important –If moving from the current service would choose the GP only option Intervention still receiving the service –Advice on medicines, satisfactory replies, chance of receiving the best medicine and cost remained most important plus advice on medicines and lifestyle –If moving from the current service would choose the combined GP-pharmacist option

39 Willingness to pay Intervention all –Valued their current service at £19.28 Intervention still receiving the service –Valued their current service at £21.99 –Would pay £50 to move to a GP-pharmacist service Control groups –Would pay £17.09 to stay with their current service rather than move to GP-pharmacist service

40 Cost benefit analysis for trial ControlIntervention allIntervention still receiving the service Mean extra benefits per patient (from DCE) -£17.09£19.28£21.99 Mean extra cost per patient £32.67£18.16 Mean net benefits per patient £-49.76£1.12£3.83

41 Decision making process Efficient allocation of resources Outcome measuresResultsEconomic evaluation Clinical outcome (Appropriateness of treatment) NO difference across groupsCost minimisation Results: increased total NHS costs with the introduction of the service QALY (EQ5D and SF6D) NO difference across groupsCost minimisation Results: increased total NHS costs with the introduction of the service DCEsDifferences across groups: Subjects who experienced the new service valued the input from their pharmacists, and preferred it to any other option Cost benefit analysis Results: The increase in intervention costs was partially compensated by increased patients valuation for that service

42 Conclusion Patients value the opportunity to have input from both pharmacist and GP Extra costs of delivering the pharmacy led medicines management service were partially offset by increased value to patients The DCE methodology: –helped understand what patients valued –quantified value of the service within a CBA –is useful for use in pharmacy policy decision making

43 Summary DCEs can inform emerging policy and evaluate implemented policy Add a dimension not otherwise available In pharmacy research has explained what stakeholders want and how it is valued

44 Thank you for listening


Download ppt "Modernising community pharmacy in Scotland- how do we know what the stakeholders want? Christine Bond Department of General Practice and Primary Care and."

Similar presentations


Ads by Google